
    
      Total study duration was up to 34 weeks: Up to 4-week screening period, 24-week open-label
      treatment phase, 6-week post-treatment observation. After completion of the treatment phase
      of this study, participants were eligible to enter a long term safety study (LTS11210 -
      SARIL-RA-EXTEND) for continuous treatment with sarilumab (SAR153191 [REGN88]).
    
  